Forty-two patients with refractory (15 patients) or relapsed (27 patients) Hodgkin's disease (HD) were included in a prospective single center study evaluating the efficacy of a regimen VIP combining etoposide 75 mg/m 2 /day days 1-5, ifosfamide 1.2 g/m 2 /day days 1-5 and cisplatinum 20 mg/m 2 /day days 1-5, one course every 4 weeks as salvage therapy in patients with refractory or relapsed Hodgkin's disease, potentially eligible for high-dose chemotherapy with reinjection of hematopoietic stem cells (HSC). If patients were considered chemosensitive after two courses of VIP, high-dose chemotherapy followed by the reinjection of HSC was planned. After two courses of VIP, 67% achieved an objective response including 38% complete responses. Overall, 28 patients went on to high-dose therapy with reinjection of HSC, and 46% of grafted patients are in a sustained complete remission. When the overall patient population is considered, 33% are in complete remission (CR) with a median follow-up of 37 months. A CR of less than 12 months and refractory disease were associated with a poor survival. These results showed that the VIP regimen is effective in relapsed or refractory HD and allows high-dose therapy to be given in the case of most responding patients. However, results in patients with refractory disease or a first complete remission of less than 12 months need to be further improved. Keywords: Hodgkin's disease; salvage therapy; VIP; etoposide; ifosfamide; cisplatinum
the length of their first remission. When patients relapse more than 1 year after the end of their first-line therapy, as many as 85% of them achieve a second complete remission when the same drug combination is used. [8] [9] [10] However, recent reports have shown that long-term disease-free survival at 15 years is achieved in only 20% of these favorable relapses. 8 Conversely, when patients relapse less than 12 months after their first CR or when they do not achieve a first CR, the results of conventional salvage therapy are worse and few long-term survivors are expected. 7, 8, [11] [12] [13] [14] High-dose chemotherapy followed by autologous hematopoietic rescue was considered a viable option because of good results achieved in a series of phase II trials. In refractory patients pooled with complete responders (Ͻ12 months), high-dose chemotherapy with reinfusion of HSC yielded CR rates of 40-80% with approximately 40% of patients free of disease at 3 years. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] High-dose chemotherapy with BMT is particularly appealing since some patients with disease refractory to conventional-dose chemotherapeutic regimens can be cured. 16, 24, 25 The BNLI compared standard salvage chemotherapy to high-dose chemotherapy with bone marrow transplantation and found higher event-free survival in the high-dose chemotherapy group. The study was, however, closed prematurely. 23 These results strengthened what was alleged in many phase II trials, namely that high-dose therapy with reinfusion of HSC can produce better results than conventional-dose chemotherapy. 23 Prognostic factors allowing the identification of a subgroup of patients who would particularly benefit from highdose therapy have been extensively sought. 16, 24, [27] [28] [29] [30] Discrepancies persist regarding their legitimacy probably due to non-homogeneous patient characteristics and selection in the different cohorts studied. 31 Of the various prognostic factors identified for long-term disease-free survival in high-dose chemotherapy trials, one of the most frequently found is the chemosensitivity of HD at the time of transplantation. 16, 24, [27] [28] [29] [30] Salvage chemotherapy before BMT could therefore play an important role in the curability of patients with primary refractory or relapsed HD.
We report here the results of a phase II trial of the VIP regimen for patients in whom intensification was envisaged early on in the course of therapy. This treatment was offered in unselected heavily pre-treated patients with poor prognosis Hodgkin's disease who were potentially eligible (aged less than 60 year, no prior extensive bone marrow irradiation and no medical contradiction) for intensive ther-apy and reinfusion of HSC. All the patients entered in this phase II trial, were analyzed whatever their response to VIP.
Patients and methods

Patients
From January 1989 to May 1995, 42 patients with refractory (n = 15) or relapsed (n = 27) HD were included in this study. Disease was considered refractory when HD persisted after front-line chemotherapy. The main patient characteristics are presented in Table 1 . The median age was 29 years old, and there were 23 men and 19 women. All the patients had been treated with chemotherapy and 20/42 patients had received at least two chemotherapy regimens (five patients three, and three patients four regimens). Among the 42 patients, 38 had been treated with the MOPP/ABV (D) regimen. The other four patients (including two with refractory primary disease and one CR shorter than 12 months) were treated with ABVD (adriamycin, bleomycin, vinblastine, deticene) or EBVP (epiadriamycin, bleomycin, VP16, prednisone).
Eleven patients had achieved a CR exceeding 12 months during the course of their disease (but all except one had been treated with MOPP/ABV (D)), 16 patients had achieved a first CR lasting less than 12 months, and five, less than 6 months. The other 15 patients had refractory primary disease. One patient had received salvage high-dose chemotherapy followed by bone marrow transplantation. The histological diagnosis was nodular sclerosis in 28 patients, mixed cellularity in 10 patients and lymphocyte depletion in four.
Radiotherapy was part of initial therapy in 30/42 patients before the salvage VIP program. Among the 12 patients who did not receive radiotherapy, all except two were patients with refractory disease (five patients) or initial stage IIIB or IV HD (five patients). Among the patients who had previously received radiotherapy, 26/30 had relapsed in the irradiated fields.
Methods
All patients were admitted to hospital for the VIP regimen. [1] [2] [3] [4] [5] . After discharge from hospital, peripheral blood counts were performed twice weekly. Packed RBCs and platelets were transfused to maintain a hemoglobin level Ͼ80 g/l and platelets at Ͼ20 × 10 9 /l. No oral antibiotic prophylaxis was given. The hematopoietic growth factor (granulocyte colony-stimulating growth factor, G-CSF) was not routinely administered. VIP was administered every 28 days.
The initial work-up at relapse included a chest X-ray, abdominal and thoracic computerized tomography, a bone marrow biopsy and a serum LDH level determination.
Response was assessed after two courses of VIP. Only three patients were not evaluable for response: two because they were free of measurable disease (they only had bone marrow involvement with systemic symptoms), and only one course of VIP was given to one patient. Complete remission (CR) was defined as the disappearance of all measurable disease for at least 4 weeks after the end of treatment, and partial remission (PR) was defined as a more than 50% reduction in the measurable tumor mass for at least 4 weeks and the disappearance of systemic symptoms.
In case of a partial response after these first two courses of VIP, high-dose chemotherapy followed by HSC rescue was offered. Patients who achieved a minor response (tumor regression of more than 25% but less than 50%) after two courses of VIP had two more courses. If a partial response was achieved after four courses, high-dose chemotherapy was planned. Patients who achieved a PR but were not eligible for high-dose therapy for medical reasons or who refused high-dose therapy were given four more courses of VIP.
Overall and disease-free survival of all patients was defined from the start of the salvage VIP program to death or failure respectively, and the duration of remission was defined as the date of documented remission to relapse. All three end-points were analyzed according to the KaplanMeier method.
Prognostic factors studied were the achievement and duration of first CR, the presence of bulky disease (tumor mass of more than 10 cm), the LDH level, relapse in a previously irradiated field and the number of chemotherapeutic regimens before VIP.
Results
Among the patients included in this phase II trial, 39/42 had measurable disease and were evaluable for response. Of the three not evaluable for response to the VIP regimen, two had bone marrow involvement associated with B symptoms and one was removed from the study after one course of VIP because of renal failure due to grade II toxicity (WHO criteria).
The main patient characteristics according to response evaluated after two courses of VIP are presented in Table 2 . The overall response rate was 69%. Among the 39 evaluable patients, 20 achieved a PR and six a complete remission. Two of the three patients without measurable disease were considered responders after two courses because bone marrow infiltration and systemic symptoms had disappeared. Four patients achieved a minor response after two courses of VIP. Three of these four patients achieved a PR after four courses and underwent high-dose chemotherapy. The fourth patient underwent allogeneic bone marrow transplant despite a minor response.
Twenty-eight of 42 (67%) patients went on to high-dose therapy followed by HSC rescue after VIP. Twenty-six of 28 had autologous HSC rescue and two patients received an allograft (of T cell-depleted allogeneic bone marrow in one case). The conditioning regimen was PEC (etoposide, cisplatinum, cyclophosphamide) in eight cases, cyclophosphamide plus TBI in six cases and BEAM (BCNU, etoposide, cytarabine, melphalan) in 14 cases.
PBSC were collected in five patients, 21 patients had an autologous bone marrow harvest and two patients were allografted. Nine patients underwent peripheral progenitor cell harvest. Only 5/9 had sufficient cells collected during one apheresis procedure (no more than three apheresis procedures were performed). Four of these five patients with an adequate HSC harvest had refractory HD and were treated with eight courses of MOPP/ABV just prior to the VIP regimen. The total number of CFU-GM was judged to be adequate to ensure engraftment in all the patients for whom a graft was planned. Patients received a median of 21.93 × 10 4 CFU-GM/kg (range 6.42-26.02 × 10 4 CFU-GM/kg). The GM-CFC threshold was 10 × 10 4 /kg for a TBI-containing conditioning regimen. As the PEC regimen was not considered myeloablative, a threshold of 6 × 10 4 /kg was considered sufficient for bone marrow reinfusion. The mean hematological recovery time (granulocyte count exceeding 500 × 10 9 /l) was 18.5 days (range 9-39 days). Only three patients treated with a bone marrow transplantation had a granulocyte count recovery period lasting more than 24 days (28, 32 and 39 days). Two of these three patients had more than 10 × 10 4 /kg GM-CFC reinfused after a BEAM, a PEC and a TBI conditioning regimen, respectively. None of our three patients with PBSC collections had more than 40 × 10 4 CFU-GM/kg collected. When the 26 patients who received autologous transplantation were studied, only 7/26 (27%) would have had sufficient CFU-GM collected to ensure the safety of an eventual second course of high-dose therapy with stem cell reinfusion.
Thirteen of these 28 patients (46%) are in sustained CR with a median follow-up of 37 months. Four of the 14 patients who did not benefit from high-dose chemotherapy responded to VIP therapy and one of them is in complete remission 67 months after VIP therapy. Of the two patients treated with allogeneic BMT, one is alive without disease 27 months after therapy (the one who received a T celldepleted graft) and the other died with active HD 5 months after allogeneic bone marrow transplantation.
When all 42 patients are analyzed (whatever their response to the salvage VIP program), 13/42 (31%) are alive in CR with a median follow-up of 37 months (range 3-71 months) including 7/31 (23%) with primary refractory HD or who experienced a first CR of less than 12 months.
VIP toxicity
No treatment-related deaths were observed. Ninety-two courses of VIP were fully assessable for hematological toxicity and other adverse effects. No hematopoietic growth factors were given with VIP for these 92 courses. Neutropenia (Ͻ0.5 × 10 9 /l) was observed in 87% of patients; it resolved in less than 1 week in all cases.
Only 46% of patients developed fever and required admission to the hospital for antibiotic therapy. RBC and platelet transfusions were given after 32% and 26% of VIP courses. Mucositis did not occur and only one course of VIP was associated with grade II renal failure linked to grade II neurologic toxicity (encephalopathy). No other toxicity was observed after VIP therapy. One toxicity-related death occurred during high-dose therapy followed by bone marrow transplantation, due to acute respiratory distress syndrome associated with a streptococcus infection.
One secondary myelodysplastic syndrome was observed 24 months after high-dose therapy.
Prognostic factors at relapse
Prognostic factors at relapse associated with response to VIP: Thirty-nine of 42 patients are evaluable for response to VIP therapy. Three patients were excluded from the analysis because of renal failure after one course of VIP (one case) and the absence of measurable evaluable disease (two cases).
Bulky disease was associated with a poor response to the VIP regimen (P Ͻ 0.02). Six of 42 patients had bulky disease when they entered the salvage VIP program and only one of them achieved a response to therapy.
The LDH level was determined in 35 patients and found to be elevated in 6/10 (60%) cases in first CR exceeding 12 months and in 14/25 (56%) cases of primary refractory HD or in first CR of less than 12 months. The LDH level and response to therapy were therefore available in 33 patients (two of whom had no measurable disease). The LDH level at relapse did not influence the rate of response to the VIP regimen; 73% of patients with a normal LDH level responded to VIP (P Ͻ 0.2) and 50% with an elevated LDH level. Response to first-line therapy (ie when patients with primary refractory disease and those who achieved a first CR of less than 12 months are compared to patients with a first CR exceeding 12 months) was associated with a better response rate to the VIP regimen, since 61% of patients with refractory disease or a CR of less than 12 months responded compared to 91% of patients with a CR exceeding 12 months (P = 0.07). No difference was found for response to the salvage VIP program when the number of previous regimens was analyzed. Thirteen of 18 patients previously treated with one chemotherapeutic regimen achieved a response to VIP compared to 13/21 patients treated with more than one chemotherapy regimen.
Neither stage IV disease nor bone marrow involvement influenced the response rate to VIP.
Prognostic factors at relapse associated with disease-free survival: Only 39 patients were studied for survival. Three patients were excluded because of death due to toxicity during bone marrow transplantation (one case), death related to secondary acute leukemia (one case) and renal failure due to toxicity after one course of VIP (one case).
No difference was observed for disease-free survival between patients who received one chemotherapy regimen before VIP and those who had received several. When all the patients evaluable for disease-free survival were studied, 6/19 patients previously treated with one regimen are in a sustained CR compared to 7/20 patients treated with more than one regimen before salvage VIP. Eight of 14 patients with a normal LDH level before VIP are in a sustained CR compared to only 3/18 patients with a high LDH level. However, when survival was analyzed using the log rank test, no difference in survival was observed between these two groups. A first CR of less than 12 months or refractory primary disease were associated with a poor DFS and a poor overall survival (Figure 1 ). Only 7/31 (23%) patients with refractory disease or with a CR of less than 12 months are in a sustained CR compared to 6/11 (54%) with a CR of more than 12 months (P = 0.07).
Discussion
Optimal treatment for relapsed or refractory Hodgkin's disease remains an area of intense clinical research. Here, we report our experience with the salvage VIP program which includes etoposide, ifosfamide and cisplatinum followed by high-dose chemotherapy in patients with chemo-sensitive Hodgkin's disease. All patients with poor prognosis relapsed HD received the salvage VIP regimen as intensification. We chose to report all the patients whatever their response to VIP, rather than to focus on the selected population that received intensified treatment, to acquire a more accurate appraisal of feasibility and efficacy of these therapeutic procedures in unselected HD patients. Our objectives were to evaluate the extent to which sufficient HSC could be obtained after salvage VIP on the one hand, and the feasibility of high-dose therapy in patients with chemosensitive HD on the other hand. Despite extensive prior therapy in most of our patients, salvage VIP, rapidly followed by reinfusion of HSC was possible in most of the responding patients. Many reports have evaluated various chemotherapy regimens associated with high-dose chemotherapy consolidation or not. 8, 13, 15, 21, 23, [32] [33] [34] [35] [36] [37] [38] [39] These phase II trials were conducted in patients who had received different prior chemotherapy regimens for their HD making it difficult to compare their results with any degree of precision. In our study, most of the patients had been treated with the eight drugs mainly used in HD and almost half of them had disease refractory to these drugs used in first-line therapy. Although our results with the VIP regimen are comparable to those yielded by conventional salvage chemotherapy regimens with 69% of patients achieving a response after two courses of VIP, they showed that only 36% of patients remain disease-free with a median follow-up of 44 months for complete remissions. This is rather disappointing, especially since high-dose therapy with reinfusion of HSC was given to patients with chemosensitive disease soon after the beginning of salvage therapy. However, if only those patients treated with high-dose therapy are considered, 46% of them are in sustained complete remissions. This is in accordance with previous studies which included selected patients treated with high-dose regimens. [15] [16] [17] 23, 24, [26] [27] [28] [29] [30] The various conditioning regimens used in our patients were not compared because patient numbers were small. Although our series is rather heterogeneous with respect to the chemotherapy conditioning regimens, none of these regimens have been shown to be superior. They are all based on high-dose alkylating agents and it is quite probable that there are no major differences between them.
A number of prognostic factors have been described that may influence the prognosis of relapsed or refractory disease. The most frequently reported are the duration of the previous complete response, age, B symptoms, the presence of extranodal disease, patient performance status and a recurrence in previously irradiated fields. 16, 24, [27] [28] [29] [30] 40 The relative role of these prognostic factors has not been firmly established by multivariate analysis. Recently, one group reported that the LDH level is an important prognostic factor in relapsed HD. 40 Of the major prognostic factors identified in our study, only the presence of refractory disease and a first CR of less than 12 months were associated with a poor disease-free survival. We did not perform a multivariate analysis because of the limited numbers of patients in this series, and because we only found one relevant prognostic factor. This major prognostic factor was identified in a population of patients treated whenever possible with high-dose therapy. Other chemotherapy conditioning regimens could be explored in these poor prognosis patients but the high level of alkylating agents resistance noted reduces the likelihood of achieving better results.
Toxicity was acceptable, with only one patient dying during high-dose therapy. No toxicity-related deaths were observed during the VIP salvage regimen. Myelosuppression was the major toxicity, with granulocytopenia lasting less than a week, associated with febrile episodes in half of the cases. This toxicity was observed in the absence of hematological growth factors. Routine support with hematopoietic growth factors should be considered because of the incidence of febrile neutropenia observed with VIP in these heavily treated patients according to recent published guidelines. 41, 42 Platelet transfusions were required because of grade IV thrombocytopenia in only 25% of cases. The myelosuppression observed with VIP did not interfere with the subsequent collection of HSC in most cases. It is noteworthy that patients were kept in hospital throughout the VIP regimen because of cisplatinum and ifosfamide infusion lasting 5 days.
In conclusion, these results indicate that the VIP regimen is active and its toxicity is tolerable in relapsed or refractory HD and allows high-dose therapy in most responders. However, despite early intensification in chemosensitive patients, results need to be improved, especially in those with refractory disease or with a first remission lasting less than 12 months.
